Five-year results of a phase ii study with low-dose bacille calmette-guérin therapy in high-risk superficial bladder cancer
- 1 June 1995
- Vol. 45 (6) , 958-961
- https://doi.org/10.1016/s0090-4295(99)80115-0
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- BCG for Carcinoma in situEuropean Urology, 1992
- Superficial Bladder Cancer Treated with Bacillus Calmette-Guerin: A Multivariate Analysis of Factors Affecting Tumor ProgressionJournal of Urology, 1989
- Single Course Versus Maintenance Bacillus Calmette-Guerin Therapy for Superficial Bladder Tumors: A Prospective, Randomized TrialJournal of Urology, 1987
- Bacillus Calmette-Guerin for Treatment of Superficial Transitional Cell Carcinoma of the Bladder in Patients who have failed Thiotepa and/or Mitomycin CJournal of Urology, 1987
- Risks and Benefits of Repeated Courses of Intravesical Bacillus Calmette-guerin Therapy for Superficial Bladder CancerJournal of Urology, 1987
- Stage T1, Grade 3 Transitional Cell Carcinoma of the Bladder: An Unfavorable Tumor?Journal of Urology, 1987
- Superficial Bladder Cancer: Progression and RecurrenceJournal of Urology, 1983
- Effect of intravesical bacillus calmette-guerin (BCG) on carcinomain situ of the bladderCancer, 1983
- Experience with Bacillus Calmette-Guerin in Patients with Superficial Bladder CarcinomaJournal of Urology, 1982
- Treatment of carcinoma in situ of the bladder with BCGCancer Immunology, Immunotherapy, 1980